Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study

References

• Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(9):1027–1041.
   PubMed Web of Science ®Google Scholar
• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295–1299.
   PubMed Web of Science ®Google Scholar
• Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54(4):752–759.
   PubMed Web of Science ®Google Scholar
• Kamijo H, Miyagaki T. Mycosis fungoides and sezary syndrome: updates and review of current therapy. Curr Treat Options Oncol. 2021;22(2):10.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ. Survival in mycosis fungoides and sezary syndrome: how can we predict outcome? J Invest Dermatol. 2020;140(2):281–283.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–3773.
   PubMed Web of Science ®Google Scholar
• Larocca C, Kupper T. Mycosis fungoides and Sézary syndrome: an update. Hematol Oncol Clin North Am. 2019;33(1):103–120.
   PubMed Web of Science ®Google Scholar
• Hothali A. G.I., review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach. Int J Health Sci. 2013;7(2):220–239.
   Google Scholar
• Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):2–10.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522–536.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2021;192(4):683–696.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–4297.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–863.
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol. 1996;34(4):626–631.
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003;49(5):873–878.
   PubMed Web of Science ®Google Scholar
• Quereux G, Marques S, Nguyen J-M, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol. 2008;144(6):727–733.
   PubMedGoogle Scholar
• Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and sezary syndrome. Am J Hematol. 2016;91(12):E491–E495.
   PubMed Web of Science ®Google Scholar
• Hughes CFM, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81.
   PubMed Web of Science ®Google Scholar
• Gao C, McCormack C, van der Weyden C, et al. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with sezary syndrome. Blood. 2019;134(16):1346–1350.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204.
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–5834.
   PubMed Web of Science ®Google Scholar
• Mehra T, Ikenberg K, Moos RM, et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome. JAMA Dermatol. 2015;151(1):73–77.
   PubMed Web of Science ®Google Scholar
• Beygi S, Fernandez-Pol S, Duran G, et al. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv. 2021;5(3):771–774.
   PubMed Web of Science ®Google Scholar
• Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Rev Anticancer Ther. 2021 Sep;21(9):1017–1028.
   Web of Science ®Google Scholar
• Weiner DM, Durgin SJ, Wysocka M et al. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: part II, current and future approaches. J Am Acad Dermatol. 2021 Mar;84(3):597–604.
   Google Scholar
• Bilimoria KY, Stewart AK, Winchester DP, et al. The national cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–690.
   PubMed Web of Science ®Google Scholar
• STATA/IC-14. 2015. College Station, TX: StataCorp, LP.
   Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Behbahani S, Yeh CJ, Fernandez JM et al. Gender differences in clinical presentation, treatment, and outcomes in mycosis fungoides. J Am Acad Dermatol. 2022 Jan;86(1):174–177.
   Google Scholar
• Su C, Nguyen KA, Bai HX, et al. Racial disparity in mycosis fungoides: an analysis of 4495 cases from the US national cancer database. J Am Acad Dermatol. 2017;77(3):497–502 e2.
   PubMed Web of Science ®Google Scholar
• Virmani P, Levin L, Myskowski PL, et al. Clinical outcome and prognosis of young patients with mycosis fungoides. Pediatr Dermatol. 2017;34(5):547–553.
   PubMed Web of Science ®Google Scholar
• Nath SK, Yu JB, Wilson LD. Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. Clin Lymphoma Myeloma Leuk. 2014;14(5):419–423.
   PubMed Web of Science ®Google Scholar
• Geller S, Lebowitz E, Pulitzer MP, et al. Outcomes and prognostic factors in african american and black patients with mycosis fungoides/Sézary syndrome: retrospective analysis of 157 patients from a referral cancer center. J Am Acad Dermatol. 2020;83(2):430–439.
   PubMed Web of Science ®Google Scholar
• Smith GL, Shih Y-CT, Xu Y, et al. Racial disparities in the use of radiotherapy after breast-conserving surgery: a national medicare study. Cancer. 2010;116(3):734–741.
   PubMed Web of Science ®Google Scholar
• Alamanda VK, Song Y, Schwartz HS, et al. Racial disparities in extremity Soft-Tissue sarcoma outcomes: a nationwide analysis. Am J Clin Oncol. 2015;38(6):595–599.
   PubMed Web of Science ®Google Scholar
• Alimena S, Yang DD, Melamed A, et al. Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecol Oncol. 2019;154(3):595–601.
   PubMed Web of Science ®Google Scholar
• Elflein J. Total Medicaid Enrollment 1966-2019 2020. [cited 2021 1/30/21]; Available from: https://www.statista.com/statistics/245347/total-medicaid-enrollment-since-1966/.
   Google Scholar
• Bureau USC. Race Data Tables. 2020. [cited 2021 1/30/2021]; Available from: https://www.census.gov/topics/population/race/data/tables.html.
   Google Scholar
• Maguire A, Puelles J, Raboisson P, et al. Early-stage mycosis fungoides: epidemiology and prognosis. Acta Derm Venereol. 2020;100(1):adv00013.
   PubMed Web of Science ®Google Scholar
• O'Malley JT, de Masson A, Lowry EL, et al. Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides. Clin Cancer Res. 2020;26(2):408–418.
   PubMed Web of Science ®Google Scholar
• Amorim GM, Niemeyer-Corbellini JP, Quintella DC, et al. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018;93(4):546–552.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2017;28(10):2517–2525.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2019;30(3):494.
   PubMed Web of Science ®Google Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–866.
   PubMedGoogle Scholar
• Martinez-Escala ME, Kuzel TM, Kaplan JB, et al. Durable responses with maintenance dose-sparing regimens of romidepsin in cutaneous T-cell lymphoma. JAMA Oncol. 2016;2(6):790–793.
   PubMed Web of Science ®Google Scholar
• Jain S, Zain J, O'Connor O. Novel therapeutic agents for cutaneous T-cell lymphoma. J Hematol Oncol. 2012;5:24.
   PubMed Web of Science ®Google Scholar
• Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.
   PubMed Web of Science ®Google Scholar
• Funk MJ, Westreich D, Wiesen C, et al. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173(7):761–767.
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350–357.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Prince HM, Cowan R, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2021;184(4):722–730.
   PubMed Web of Science ®Google Scholar